HALOZYME THERAPEUTICS, INC. (HALO) Gross margin 2016–2025
HALOZYME THERAPEUTICS, INC. (HALO) gross margin by fiscal year — reported gross profit divided by reported revenue.
83.6%FY2025 · since FY2016: 77.4% → 83.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 83.6% | -0.7 pp |
| FY2024 | 84.3% | +7.5 pp |
| FY2023 | 76.8% | -2.1 pp |
| FY2022 | 78.9% | -2.7 pp |
| FY2021 | 81.6% | -2.2 pp |
| FY2020 | 83.8% | +7.0 pp |
| FY2019 | 76.8% | -16.6 pp |
| FY2018 | 93.3% | +3.2 pp |
| FY2017 | 90.2% | +12.8 pp |
| FY2016 | 77.4% | — |
Gross margin = reported gross profit ÷ reported revenue for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More HALO financial trends
HALO RevenueHALO Net incomeHALO Net marginHALO Gross profitHALO Operating incomeHALO Operating marginHALO Operating cash flowHALO Free cash flowHALO Capital expendituresHALO Return on equityHALO Stock buybacksHALO Dividends paidHALO Total assetsHALO Total liabilitiesHALO Shareholders’ equityHALO overview →